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Available online 11 January 2012Background: Acute coronary syndromes (ACS) represent a difficult challenge for physicians.
Risk scores have become the cornerstone in clinical and interventional decision making.
Methods and results: PubMed was systematically searched for ACS risk score studies. They were
divided into ACS studies (evaluating Unstable Angina; UA, Non ST Segment ElevationMyocardial
Infarction; NSTEMI, and ST Segment ElevationMyocardial Infarction; STEMI), UA/NSTEMI studies
or STEMI studies. The c-statistics of validation studies were pooled when appropriate with
random-effect methods. 7 derivation studies with 25,525 ACS patients and 15 validation studies
including 257,654 people were formally appraised. Pooled analysis of GRACE scores, both at
short (0.82; 0.80–0.89 I.C 95%) and long term follow up (0.84; 0.82–0.87; I.C 95%) showed the
best performance, with similar results to Simple Risk Index (SRI) derivation cohorts at short
term. For NSTEMI/UA, 18 derivation studies with 56,560 patients and 18 validation cohorts
with 56,673 patients were included. Pooled analysis of validations studies showed c-statistics of
0.54 (95% CI=0.52–0.57) and 0.67 (95% CI=0.62–0.71) for short and long term TIMI validation
studies, and 0.83 (95% CI=0.79–9.87) and 0.80 (95% CI=0.74–0.89) for short and long term
GRACE studies. For STEMI, 15 studieswith 134,557 patients with derivation scores, and 17 valida-
tion studies with 187,619 patients showed a pooled c-statistic of 0.77 (95% CI=0.71–0.83) and
0.77 (95% CI=0.72–0.85) for TIMI at short and long term, and a pooled c-statistic of 0.82 (95%
CI=0.81–0.83) and 0.81 (95% CI=0.80–0.82) for GRACE at short and long terms respectively.
Conclusions: TIMI and GRACE are the risk scores that up until now have been most extensively
investigated, with GRACE performing better. There are other potentially useful ACS risk scores
available however these have not undergone rigorous validation. This study suggests that
these other scores may be potentially useful and should be further researched.
© 2012 Elsevier Inc. All rights reserved.Keywords:
Acute coronary syndrome
Risk score
Meta-analysis
Prognosis
Percutaneous coronary revascularization
Surgical coronary revascularization
Systematic reviewUniversity of Turin, S.
e 88-90, 10126 Turin,
'Ascenzo).
ll rights reserved.1. Introduction
Acute coronary syndromes (ACS) represent a wide clinical
spectrum, ranging from unstable angina (UA) to ST Elevation
Myocardial infarction (STEMI). There is heterogeneity of
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ACS spectrum [1,2].
The use and development of dedicated scores to discrim-
inate patients at high risk of serious adverse events from
low risk ones has been suggested and encouraged by many
cardiology expert groups in order to allow accurate therapeu-
tic and diagnostic decision making. [3] Risk assessment re-
mains crucial as the benefits of more aggressive and costly
treatments are greatest in patients at higher risk of adverse
clinical events [4–6].
Much effort has therefore been put into designing risk
scores for ACS patients. The two most commonly used being
the Global Registry in Acute Coronary Events (GRACE) [4]
and the Thrombolysis in Myocardial Infarction (TIMI) [7]
scores. Both are derived from landmark ACS studies and
have undergone wide prospective evaluation. More recently
other scores have been designed to focus on clinical risk
assessment and to improve the selection of patients for
clinical and interventional procedures.
Despite the presence of many validation studies confirm-
ing the validity of GRACE and TIMI in multiple clinical set-
tings, to our knowledge there has been no meta-analysis to
systematically compare their discriminatory performance.
We therefore aimed to undertake a systematic review to as-
sess ACS risk evaluation scores in order to determine the
most accurately performing.
2. Methods
Current guidelines, including the recent Preferred
Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) amendment to the Quality of Reporting of Meta-
analyses (QUOROM) statement, as well as recommendations
from The Cochrane Collaboration and Meta-analysis Of
Observational Studies in Epidemiology (MOOSE) were fol-
lowed during the course of this work [6–10].
2.1. Search strategy
MEDLINE/PubMed was searched for relevant English
language articles using established methods [21] and the
standard use of wild cards (identified by *): acute coronary
syndrome* AND risk score AND validation cohort AND
english[lang] NOT (review[pt] OR editorial[pt] OR letter
[pt]), or acute coronary syndrome AND risk score* AND deri-
vation cohort AND english[lang] NOT (review[pt] OR editorial
[pt] OR letter[pt]).
Abstracts from scientific meetings and references of all
included studies were also searched and appraised.
2.2. Study selection
Retrieved citations were first screened independently by
two unblinded reviewers (GBZ, FDA) at the title and/or ab-
stract level, with disagreements resolved by consensus. The
full text of all potentially relevant articles were then fully ap-
praised using the following explicit selection criteria, which
were piloted over the first 5 studies to ensure consistency
and discrimination. Inclusion criteria were (all had to be
met for inclusion): (i) Human studies, (ii) Studies investigat-
ing patients presenting to hospital with ACS (i.e.UA, NSTEMIand STEMI), (iii) Risk score derivation or validation studies
(or both) and (iv) Studies appraising scores using multivari-
ate analysis. Exclusion criteria were (any single one enough
for exclusion): (i) Non-human setting, (ii) Duplicate report-
ing (in which case the manuscript reporting the largest sam-
ple of patients with ACS was selected, or if equal, the study
with the largest number of overall patients), or (iii) studies
reporting only multivariate predictors, without prediction
score.
2.3. Data extraction
The following data were independently abstracted by two
unblinded reviewers (GBZ, FDA) on pre-specified electronic
forms, which were piloted over the first 5 studies to ensure
consistency and discrimination, with disagreements resolved
by consensus.
Studies were first divided according to ACS clinical pre-
sentation i.e. UA, NSTEMI and STEMI or UA/NSTEMI studies
or STEMI studies. Information recorded included authors de-
tails, journal, year of publication, location of the study group,
baseline, angiographic and procedural features, kind of revas-
cularization (fibrinolysis, percutaneous coronary interven-
tion, coronary artery bypass graft), short and long term
rates of adverse events (including death, myocardial infarc-
tion, revascularization procedures and Major Adverse Cardiac
Events; MACE), and risk score, with respective AUC (area
under the curve), c-index or c-statistic with 95% confidence
intervals. End points evaluated were c-index of the deriva-
tion risk scores and their performance when tested in valida-
tion cohorts.
2.4. Internal validity and quality appraisal
The quality of included studies was independently ap-
praised by two unblinded reviewers (GBZ, FDA), on pre-
specified electronic forms, which were piloted over the first
5 studies to ensure consistency and discrimination, with dis-
agreements resolved by consensus.
Modifying the MOOSE item list in order to take into ac-
count the specific features of included studies [8], we sepa-
rately abstracted and appraised study design, setting, data
source and statistical methods for multivariable analysis, as
well as, in keeping with The Cochrane Collaboration ap-
proach, the risk of analytical, selection, adjudication, detec-
tion and attrition bias (expressed as low, moderate, or high
risk of bias, as well as incomplete reporting leading to inabil-
ity to ascertain the underlying risk of bias).
2.5. Data analysis and synthesis
Continuous variables are reported as mean (standard devi-
ation) or median (range). Categorical variables are expressed
as n/N (%). Statistical pooling was performed according to a
random-effect model with generic inverse-variance weighting
and computing c-index of the validation scores with 95% confi-
dence intervals using RevMan 5 (The Cochrane Collaboration,
The Nordic Cochrane Centre, and Copenhagen, Denmark).
Sensitivity analysis was performed to appraise small study
bias by graphically inspecting funnel plots (Figure A, appendix,
Fig. 1. Study flow diagram.
509F. D'Ascenzo et al. / Contemporary Clinical Trials 33 (2012) 507–514web only figure). The parallel fixed-effect model was also used
to confirm our results.
3. Results
Data search and study selection are summarized in Fig. 1.
3.1. ACS
7 derivation studies [7,11–16] with 25,525 ACS patients
and 15 validation studies [16–30] including 257,654 people
were formally appraised. Baseline clinical features of
included patients were similar (Table 1). The majority of
patients were male. GRACE and SRI validation studies had a
lower rate of Unstable Angina diagnosis and a higher rate of
NSTEMI and STEMI diagnosis. Among all studies, aboutTable 1
Baseline characteristics ACS studies.
Derivation studies
[7,11–16] (7 studies,
25,535 patients)⁎
TIMI validation stu
[17–25] (9 studies
127,383 patients)
Patients 1501 (308–5940) 703 (411–900)
Male gender 66 (65–67) 64 (62–68)
Age (years) 65 (61–69) 63 (61–66)
Pts presenting with UA 43 (7–57) 45 (11–84)
Pts presenting with NSTEMI 43 (32–45) 31(12–41)
Pts presenting with STEMI 34 (24–39) 24 (2.5–64)
Pts undergoing PTCA 77 (63–88) 66 (62–69)
Pts undergoing CABG 19 (13–22) 6 (3–8.5)
Follow up (days) 90 (30–365) 60 (30–292)
Mace 12 (9–14) 6 (4–6.8)
Death 5 (4–5.5) 5 (2.6–6.3)
AMI 2 (2–5.5) 3 (2–4.5)
⁎ Reported as median (1st; 3rd quartile) or n/N (with patients or studies as deno
⁎⁎ Simple risk index.three quarters of patients underwent a percutaneous revas-
cularization, with rates of MACE ranging from 4.7% to 11%
and of death from 4.2% to 11%. The short term TIMI AUC
was 0.66 (95% CI=0.64–0.68) and 0.73 (95% CI=0.69–
0.78) in derivation and validation cohorts respectively.
GRACE short term derivation and validation AUC was 0.83
(95% CI=0.82–0.84) and 0.82 (95% CI=0.80–0.89). The
Schiele et al. [16] score was the only one to perform similarly,
with an AUC in the short term derivation cohort of 0.82 (95%
CI=0.80–0.82). The long term AUC of the GRACE score was
0.84, while for the Zhong et al. [15] score the AUC was 0.81
(95% CI=0.71–0.86).
3.2. UA/NSTEMI
18 derivation studies [7,11,20,31–45] with 56,560 UA/
NSTEMI patients and 18 validation cohorts [18,20,22,24,28,
30,32–36,46–52] with 56,673 patients were included. As in ACS
studies, validation cohorts included more NSTEMI patients than
derivation ones (Table 2), with rates of PTCA ranging from 26
to 48%. Pooled analysis of TIMI validation studies showed an
AUC of 0.54 (95% CI=0.52–0.57) and 0.67 (95% CI=0.62–
0.71) at short and long term. AUC was 0.83 (95% CI=0.79–
9.87) and 0.80 (95% CI=0.74–0.89) for GRACE validation studies
(Figs. 3 and 4). The short term AUC for the Correia et al. [33]
study was 0.82 (95% CI=0.80–0.94) and for AMIS [20] was
0.87 (95%CI=0.86–0.88). At long termno scores performedbet-
ter than TIMI or GRACE, apart from several which had combined
TIMI and GRACE with other variables.
3.3. STEMI
15 derivation studies [53–67] of 134,557 patients and 17
validation studies [18,20,22,28,30,33,46,57,60,61,68–72] with
187,619 patients were included. Between 71 and 100% of
patients underwent PCI, and PTCA (Table 3) was more fre-
quently performed in validation cohorts than in derivation co-
horts. AUC (Fig. 6)was 0.77 (95%CI=0.71–0.83) and 0.77 (95%
CI=0.72–0.85) for TIMI at short and long term, and 0.82 (95%
CI=0.81–0.83) and 0.81 (95% CI=0.80–0.82) for GRACE at
short and long term. At short term, the CADILLAC score [59]dies
,
⁎
GRACE validation studies
[16,18,21–23,25–30]
(11 studies, 121,944 patients)⁎
SRI⁎⁎ validation studies
[18,20,29] (3 studies,
109,944 patients)⁎
1057 (722–1770) 4223 (900–1770)
65 (63–69) 64.5 (61.5–69)
65 (63–66) 67.5 (65.3–66)
21 (10–37) 23 (13.5–37)
41 (30–43) 40.5 (37–43)
41 (28–47) 48 (26.3–47)
65 (22–67) 65 (65–67)
11 (7.1–11) 11 (11–78)
181 (112–244) 315 (290–244)
4.7 (3.8–6.1) 5 (5–6.1)
4.2 (3.1–7.2) 11 (9–7.2)
1.05 (0.6–1.5) –
minators, as appropriate).
Table 2
Baseline characteristics of UA/NSTEMI studies.
Derivation studies
[7,11,20,31–45]
(18 studies, 56,560 patients)
TIMI validation studies
[18,20,24,33,35,36,46–51]
(12 studies, 18,781 patients)
GRACE validation studies
[22,28,30,32–34,46–51]
(12 studies, 36,517 patients)
Pursuit validation
studies [49,52]
(2 studies, 2065 patients)
Patients 540 (440–2073) 882 (500–1001) 1226 (450–1770) 1033 (900–1770)
Male gender 66 (65–68) 61(60–67) 65 (63–69) 65.5 (61.5–69)
Age (years) 64.5 (62–66) 64 (61–67) 66 (61–69) 67.5 (62–69)
Pts presenting with UA 54 (39–68) 41.5 (27–70) 40 (23–52) 22 (11–33)
Pts presenting with NSTEMI 46 (32–57) 58.5(31–73) 56 (48–77) 78 (65–87)
Pts undergoing PTCA 27 (21–33) 48 (35–51) 26 (22–38) 27 (20–33)
Pts undergoing CABG 13 (12–27) 12 (7–5–12.5) 8.5 (6.5–9.5) 8.5 (6.7–8.8)
Follow up (days) 30 (12–360) 30 (12–180) 180 (120–180) 360 (290–392)
Mace 30 (14–60) 8 (6.5–9.7) 5.8 (4.2–8.2) –
Death 4.7 (3.4–11.4) 7.5 (5.3–11) 7.5 (7–14) –
AMI 4.8 (2.2–10) 5 (2.6–4.5) 1.8 (1.4–2.2) –
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95% CI=0.82–0.84), Lee et al. [62] (0.86; 9%% CI=0.84–0.86)
and Peterson et al. [65] (0.90; 95% CI=0.89–0.91). Long term
AUC values for APEXAMI [66], PAMI [53], Khan et al. [61], Dam-
man et al. [55] and Urbonaviciene et al. [67] studies were also
good. These studies, are all showing comparable performance
to TIMI and GRACE scores, are all derivation studies which
have not yet been externally validated (Figs. 1–5). Results of
studies reporting AUC values inferior to GRACE or TIMI are
reported in Table D, Appendix.
4. Discussion
The most important findings of our meta-analysis are: a)
There is a striking difference in the rates of patients undergo-
ing invasive revascularization between derivation and valida-
tion studies, b) TIMI and GRACE risk scores are the only
scores which have been validated in all types of ACS, with
the GRACE score performing better, c) many other risk
scores, which show good performance in a derivation cohort,
have not yet been evaluated in validation cohorts.
Derivation and validation studies evaluated in our review
are quite heterogeneous from a methodological point of
view. While about half of derivation studies consist of data0
Pooled analysis of  GRACE validation for death, ami and
revascularization at long term*** 
GRACE derivation for death at six month
Zhong derivation for death at 365 days
Pooled analysis of GRACE validation for death,
ami and revascularization at short term*
GRACE derivation for death in hospital
Schiele derivation for death at 30 days
Pooled analysis of TIMI validation for death, ami and
revascularization at short term*
TIMI derivation for death, AMI, and revascularization
at 14 days
Fig. 2. Short and long term Area Under the Curve for derivation and validation scores
better than the latter were reported. (*in hospital and 30 days follow up; ** 185 d
Tau²=0.00; Chi²=79.53, df=6 (Pb0.00001); I²=92%.derived from randomized clinical trials, almost all validation
study data came from observational registries, most of them
located in Europe and in North America. The application of
data from highly selected cohorts to everyday life may under-
mine the reproducibility of these scores.
Patients in all studies are similar in baseline characteristics,
with some differences in the rate of revascularization proce-
dures. This was especially marked in studies evaluating UA/
NSTEMI or STEMI alone with higher revascularization rates in
validation cohorts. It is worth noticing that, apart from STEMI
patients, and despite recent guidelines no more than half of
overall patients have undergone percutaneous or surgical re-
vascularization, with an important burden of unfavorable ef-
fects, both for short and long term outcomes, as recently
demonstrated [73,74]. The effect of these management strate-
gies in derivation cohorts could also affect variables resulting
in independent predictors of adverse events, thus underlying
the need of new scores using more contemporary databases.
Our work confirms that TIMI and GRACE risk scores are
the only ones validated in multiple clinical setting, with
GRACE showing a better performance with an AUC around
0.85. In all the studies, the highest AUC values are around
0.85. This is a satisfactory performance when compared to
clinical scores for other medical conditions. [75–77]. For0,84
0,81
0,81
0,82
0,83
0,82
0,73
0,66
1 1
of ACS. For scores other than TIMI and GRACE, only those with a performance
ays (158–234); *** 180 days (180–360)). Heterogeneity for pooled results:
0,86
0,84
0,81
0,80
0,81
0,67
TIMI and proBNP derivation for death at
720 days 
GRACE and gdf15 derivation for death at
2088 days
GRACE and cystatin derivation for death at
2088 days 
Pooled analysis  of GRACE validation for death,
ami and refractory angina at long term** 
GRACE derivation for death at six months 
Pooled analysis of TIMI validation for death,
ami and revascularization at long term*   
Fig. 4. Long termAreaUnder the Curve for derivation and validation scores of UA/
NSTEMI. For scores other than TIMI and GRACE, only those with a performance
better or equal than the latter were reported. (⁎360 days (315–361);
⁎⁎180 days (180–360)). Heterogeneity for pooled results: Tau²=0.00;
Chi²=29.40, df=5 (Pb0.0001); I²=83%.
0,83
0,82
0,87
0,93
0,87
0,82
0,54
0,66
Pooled analysis of GRACE validation
for death, ami at short term
GRACE derivation for death in hospital 
TIMI and troponin and ECG changes
for death, ami at 30 days 
TIMI and PCR derivation for death in hospital
AMIS derivation for death in hospital
Correia derivation for death in hospital
Pooled analysis of TIMI validation for
death, ami in hospital 
TIMI derivation for death, AMI, and
revascularization at 14 days 
Fig. 3. Short term Area Under the Curve for derivation and validation scores
of UA/NSTEMI. For scores other than TIMI and GRACE, only those with a per-
formance better or equal than the latter were reported. Heterogeneity for
pooled results: Tau²=0.00; Chi²=0.02, df=2 (P=0.99); I²=0%.
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idation cohorts, both for evaluating short term outcomes and
especially long term outcomewhich has been shown recentlyTable 3
Baseline characteristics of STEMI studies.
Derivation studies
[53–67] (15 studies,
134,457 patients)
TIMI validation studie
[18,20,33,46,57,60,61,
(12 studies, 164,835 p
Patients 2485 (1412–9690) 885 (553–7520)
Male gender 74 (67–78) 62(59–67)
Age (years) 62.5 (62–66) 64 (61–67)
Pts undergoing fibrinolysis 100 (0–100) 15.5 (0–64)
Pts undergoing PCI 100 (12–64) 71 (38–100)
Pts undergoing PTCA 31 (25–64) 60.5 (30–72)
Pts undergoing CABG 21 6 (3–9.7)
Follow up (days) 30 (30–290) 270 (143–11)
Mace 5 (5–10) 5 (3.5–4.5)
Death 6 (4–7) 7.5 (7–12)
AMI 3 (2–4) –
Revascularization 13 (12–20) –to be a challenge. [74] The only notable exception is the per-
formance of TIMI with the addition of proBNP for long term
outcome prediction in UA/STEMI [36], which performed bet-
ter than GRACE. Another interesting finding is that some risk
scores (both new scores and scores derived from TIMI with
additional variables) show a comparable AUC to GRACE in
their derivation cohorts, but without external validation
their relevance is limited. For example, for studies evaluating
ACS, the Schiele et al. [16] study and the Zhong et al. [15]
study offer similar AUC to the AUC of Correia et al. [33] and
AMIS [20] for UA/NSTEMI at short term. Interestingly only
scores adding gdf15 or cystatin to GRACE [34] or pro-BNP to
TIMI [36] perform similarly for patients with UA/NSTEMI.
While the first two predictors may be difficult to exploit in
everyday clinical practice, the latter could be very useful to
guide management of these patients.
On the contrary, for STEMI patients many scores per-
formed with similar AUC for both short term [54,59,62,65]
and long term [53,55,61,67,66] outcomes. If this is confirmed
in validation studies, they could provide physicians a power-
ful tool to discriminate high risk patients. This is particularly
true for more recently derived scores which include patients
treated with the most modern medical and interventional
strategies. There were several studies that performed poorly.
The reason for this can only be guessed however maybe relat-
ed to poor selection of patients or to statistical methodology.
The present work has several limitations. We considered
only studies that had at least one analysis performed to as-
sess incremental predictive ability. Many other articles
reporting only risk factors without a clear evaluation of pre-
diction were excluded, and it is important to remember that
empirical evidence in other fields, for example cancer, sug-
gest that new predictors are almost always significant [78].
Moreover, as suggested from visual inspection by funnel
plot, no publication bias was reported. (Figure A, appendix,
web only figure). Most of the included studies reported a
low or moderate risk of selection and attrition bias, while at-
trition and adjudication were mostly appraised as moderate.
(Table A, B and C, appendix, web only tables). Heterogeneity
ranged from low to high, thus we performed our analysis
with random effect methods; however we also used fixed
models, with no effect on AUC.s
68–72]
atients)
GRACE validation studies
[22,28,30,46,50,51,68,69]
(8 studies, 12,204 patients)
Cadillac validation
studies [68,69]
(2 studies, 1360 patients)
602 (456–1495) 1033 (900–1770)
67.5 (62–71) 65.5 (61.5–69)
65 (61–69.5) 67.5 (62–69)
0
74.5 (42.5–100) –
71 (58.6–71) 36 (29–39)
9.1 (8.1–10) 6 (3–9.7)
180 (180–315) 270 (143–11)
3.7 (3.3–5.5) 5 (3.5–4.5)
6.7 (6.3–14)
–
–
0,88
0,81
0,81
0,81
0,79
0,78
0,78
0,77
0,82
Urbonaviciene derivation for death
at 500 days 
Pooled analysis of  GRACE validation
for death at long term** 
Grace derivation for death at six months 
Damman derivation for death at 360 days
Khan derivation for death at 700 days
Pooled analysis of  CADILLAC
validation for death at 360 days 
PAMI derivation for death at 180 days
Pooled analysis of  TIMI validation for
death at long term* 
APEX-AMI for death at 90 days
Fig. 6. Long term Area Under the Curve for derivation and validation scores
of STEMI. For scores other than TIMI and GRACE, only those with a perfor-
mance better than the latter were reported. (*360 days (225–360)
**180 days (180–360)). Heterogeneity for pooled results: Chi²=419.01,
df=6 (Pb0.00001); I²=99%.
0,9
0 1 1
0,84
0,82
0,86
0,83
0,76
0,81
0,77
0,78
0,78
0,78
Peterson derivation for death in hospital
Pooled analysis of  GRACE validation for
death at 30 days
GRACE derivation for death in hospital
Lee derivation for death at 30 days
Chang derivation for death at 30 days
Pooled analysis of  CADILLAC validation for
death at 30 days
CADILLAC derivation for death at 30 days 
Pooled analysis of  TIMI validation for death
and heart failure at short term 
TIMI derivation for death at 30 days
TIMI and ST resolution for death at 30 days
TIMI SRI for death a 3 days
Fig. 5. Short term Area Under the Curve for derivation and validation scores of STEMI. For scores other than TIMI and GRACE, only those with a performance better
or equal than the latter were reported. Heterogeneity for pooled results: Tau²=0.00; Chi²=77.83, df=5 (Pb0.00001); I²=94%.
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TIMI and GRACE are the risk scores that up until now have
been most extensively investigated, with GRACE performing
better. There are other potentially useful ACS risk scores
available however these have not undergone rigorous
validation. This study suggests that these other scores may
be potentially useful and should be further researched.Disclosures
None.Appendix A. Supplementary data
Supplementary data to this article can be found online at
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